TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8462205
Drug: Dermatan sulfate
Normalized name: dermatan sulfate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulfate (DS) 6 mg/kg body weight
Study: 8462205
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin treatment
Study: 3756057
Drug: Metoprolol (M)
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol (M) 0.2 mg kg‐1 i.v. and dihydralazine (DH) 0.2 mg kg‐1 i.v.
Study: 3756057
Drug: Dihydralazine (DH)
Normalized name: dihydralazine
DrugBank: Dihydralazine (DB12945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (DH) 0.2 mg kg‐1 i.v. alone
Study: 29776872
Drug: Oral Glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucose
Study: 25987694
Drug: Enoxaparin (low-molecular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (low-molecular weight heparin)
Study: 25987694
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (observation group)
Study: 17512256
Drug: Intravenous amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amitriptyline 25 mg
Study: 17512256
Drug: Intravenous amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amitriptyline 50 mg
Study: 17512256
Drug: Intravenous amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amitriptyline 100 mg
Study: 15152535
Drug: Rectal naproxen
Normalized name: naproxen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal naproxen
Study: 2453226
Drug: Peroral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroral administration
Study: 2453226
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration
Study: 23985411
Drug: Sildenafil (started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (started 2 weeks before surgery and continued postoperatively at 0.5 mg/kg, increased to a maximum of 2 mg/kg)
Study: 23985411
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sildenafil started only postoperatively at 0.5 mg/kg, increased to a maximum of 2 mg/kg)
Study: 16503536
Drug: Trimetazidine 20
Normalized name: trimetazidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 20 mg 3 times daily for 8 weeks
Study: 16503536
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy (Control group A)
Study: 14550702
Drug: Vibrating gel-based
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vibrating gel-based insoles
Study: 8936659
Drug: Corticosteroid (prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (prednisone 1 mg/kg/day in decreasing doses)
Study: 6388810
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy for first breast cancer
Study: 23628617
Drug: Lixisenatide 20
Normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 20 μg
Study: 29548848
Drug: Resveratrol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (200 mg/day) for 26 weeks
Study: 27144849
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg daily)
Study: 20629075
Drug: Rotigotine 2
Normalized name: ROTIGOTINE 2MG/24HRS PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine 2 mg/24 hr
Study: 20629075
Drug: Rotigotine 3
Normalized name: ROTIGOTINE 3MG/24HRS PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine 3 mg/24 hr
Study: 15546135
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose melphalan (180 mg/m²) with autologous bone marrow support
Study: 10420071
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) 1 mg/kg body weight
Study: 10420071
Drug: Combined LMWH-adjusted
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined LMWH-adjusted dose plus UFH 2,500 IU fix dose (ComHep)
Study: 10420071
Drug: UFH 2,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH 2,500 IU fix dose (FixUFH)
Study: 22442350
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who continued maintenance or received a second high-dose melphalan
Study: 12800397
Drug: Thrombolytic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thrombolytic infusion during transport to PCI center for coronary angioplasty (Group B)
Study: 12396323
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) 6 mg/kg
Study: 8731761
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ivermectin (IVR) 400 micrograms/kg and Diethylcarbamazine (DEC) 6 mg/kg
Study: 2013676
Drug: Aspartame (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (up to 2000 mg)
Study: 7048338
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg labetalol 3-times daily
Study: 7048338
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg alpha‐methyldopa 3-times daily
Study: 17414235
Drug: Low-concentration desipramine
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-concentration desipramine (<60 ng/mL)
Study: 17414235
Drug: Higher concentrations
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher concentrations of desipramine (>60 ng/mL)
Study: 17414235
Drug: All concentrations
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All concentrations of fluoxetine
Study: 15808325
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fish oil (14 g/day)
Study: 8593095
Drug: Sulacillin (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulacillin (a combination of sodium ampicillin and sulbactam in a 2:1 ratio)
Study: 2923085
Drug: Milk (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (900 mg Ca daily)
Study: 2923085
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium chloride (CaCl, 900 mg Ca daily)
Study: 2923085
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CaCO3, 900 mg Ca daily)
Study: 2923085
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements (milk, CaCl, CaCO3)
Study: 337536
Drug: Intradermal method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal method of vaccination
Study: 337536
Drug: Japanese BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese BCG vaccine (percutaneous)
Study: 30170952
Drug: NaHCO3− (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3− (0.3 g.kg−1 body weight)
Study: 28615070
Drug: Tildipirosin 4
Normalized name: tildipirosin
DrugBank: Tildipirosin (DB11470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildipirosin 4 mg/kg, subcutaneously (n = 109)
Study: 10941877
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (0.58 g EPA plus 1.67 g DHA per day)
Study: 10941877
Drug: Two most
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two most concentrated fish oil supplements
Study: 10941877
Drug: Linseed oil
Normalized name: linseed oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linseed oil and fish oil supplements
Study: 30910492
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg orally, once daily 3 times a week for 2 years)
Study: 26938813
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering medication (fixed combination of perindopril and indapamide)
Study: 24215848
Drug: Bevacizumab added
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab added to capecitabine monotherapy
Study: 22433778
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of sulphadoxine‐pyrimethamine (SP)
Study: 22433778
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of sulphadoxine‐pyrimethamine (SP)
Study: 15296819
Drug: placebo/desipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo/desipramine (50 mg)
Study: 15296819
Drug: placebo/haloperidol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo/haloperidol (2 mg)
Study: 15296819
Drug: desipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: desipramine (50 mg)/haloperidol (2 mg)
Study: 15296819
Drug: desipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: desipramine (50 mg)
Study: 15296819
Drug: haloperidol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (2 mg)
Study: 10891977
Drug: High-dose creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose creatine (150 mg/kg body weight) followed by low-dose creatine (60 mg/kg)
Study: 31333778
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy combined with radiotherapy
Study: 24118234
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D supplements during pregnancy
Study: 24118234
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplements during pregnancy
Study: 11866001
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 microg once daily
Study: 30101329
Drug: Combination (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (both interventions)
Study: 26610166
Drug: Oxycodone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone treatment
Study: 26610166
Drug: Oxycodone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone treatment with secretagogues (PGE2, theophylline, ouabain)
Study: 26610166
Drug: Morphine application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine application
Study: 24716681
Drug: Tenecteplase plus
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenecteplase plus heparin
Study: 20858697
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of observation followed by one cycle of CC therapy (Group B)
Study: 12930613
Drug: Mebendazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (200 mg three times daily for 3 days)
Study: 12930613
Drug: Secnidazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secnidazole (30 mg/kg, in a single dose)
Study: 1458765
Drug: 0.2mg moxonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2mg moxonidine twice daily
Study: 1458765
Drug: 0.2mg digoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2mg digoxin once daily
Study: 27997679
Drug: Ledipasvir-sofosbuvir (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir-sofosbuvir (90 mg ledipasvir and 400 mg sofosbuvir once daily for 12 weeks)
Study: 25054452
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (3.0 g/day of EPA and DHA)
Study: 22243363
Drug: In-treatment serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment serum K ≤ 3.90
Study: 19544230
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cytology and histology
Study: 11878178
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy with technical accessories and splints
Study: 9747912
Drug: Rilmenidine (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine (1-2 mg/day)
Study: 1956211
Drug: Nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40 mg/day)
Study: 3076795
Drug: Methyldopa (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (750 mg daily)
Study: 28258828
Drug: DNA-TGN concentration
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA-TGN concentration during maintenance therapy
Study: 19503783
Drug: Risedronate 150
Normalized name: risedronate 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 150 mg once a month
Study: 15186934
Drug: Ivermectin (150-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (150-200 microg/kg body weight) + Albendazole (400 mg)
Study: 9667292
Drug: Meperidine (0.15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (0.15, 0.30, or 0.60 microg/ml)
Study: 9667292
Drug: Sufentanil (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.1, 0.15, or 0.2 ng/ml)
Study: 6783707
Drug: Sequential study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential study (6 persons subinoculated with malaria-rich blood)
Study: 26551196
Drug: Sequential combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combination of both solutions
Study: 25886386
Drug: Astragaloside IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragaloside IV (AS-IV) treatment
Study: 25886386
Drug: 4-phenyl butyric
Normalized name: 4-Phenyl-n-butyric acid
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-phenyl butyric acid (PBA) treatment
Study: 24014917
Drug: Statin medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin medication (Group-I)
Study: 24014917
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin medication (Group-II)
Study: 1146928
Drug: Ethynylestradiol or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethynylestradiol or mestranol with 2.5 mg norethindrone acetate, 2 mg megestrol acetate, or 0.5 mg norgestrel
Study: 1146928
Drug: Ethynylestradiol or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethynylestradiol or mestranol (various doses)
Study: 1146928
Drug: Ethynylestradiol or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethynylestradiol or mestranol with progestational agent
Study: 1146928
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral contraceptives
Study: 1146928
Drug: Estrogen agents
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen agents (50 to 75 mug per day)
Study: 1146928
Drug: Normal controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal controls (IUD cycles) and chronic treatment with oral contraceptives
Study: 31332029
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 400 IU b.i.d. plus pioglitazone 45 mg/day
Study: 29231585
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus western medicine
Study: 29231585
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both groups after treatment
Study: 24858769
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) for three menstrual cycles
Study: 24858769
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) for more than three cycles
Study: 24858769
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (women who never used ovulation drugs)
Study: 12605431
Drug: Low power
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low power laser therapy + exercise
Study: 12605431
Drug: Low power
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low power laser therapy alone
Study: 9356536
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (100 mg elemental Fe/d)
Study: 2645988
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine sulfate tablet (MS Contin) given every 12 hours
Study: 2720576
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine sulfate solution (MSS) given every 4 hours
Study: 31881407
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (Control Condition)
Study: 29156152
Drug: DHA-rich supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich supplements
Study: 23141686
Drug: Negative-pressure wound
Normalized name: Microcyn Negative-Pressure Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-pressure wound therapy (NPWT) applied from the first postoperative day (POD) to the seventh POD.
Study: 23141686
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no NPWT treatment).
Study: 11120549
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium acetate (5.6 g/day)
Study: 11120549
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (6.2 g/day)
Study: 8421037
Drug: Positive radiographs
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive radiographs treatment (cast for 12 weeks)
Study: 3891284
Drug: Pentazocine 0.5
Normalized name: naloxone-pentazocine 0.5 mg-50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 0.5 mg/kg
Study: 30656404
Drug: Dexmedetomidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.0 µg/kg/hr for 1 hour, followed by 0.2 µg/kg/hr)
Study: 25407009
Drug: Group schema
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group schema therapy (GST)
Study: 25276703
Drug: Inhaled lavender
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled lavender scent 30 minutes before IUD insertion
Study: 25276703
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation 30 minutes before IUD insertion
Study: 25276703
Drug: Inhaled lavender
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled lavender scent
Study: 16104966
Drug: CDC (calculus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDC (calculus deattachment with Gracey curettes and brushing with saline solution)
Study: 16104966
Drug: CDUS (calculus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDUS (calculus deattachment with ultrasonic device and brushing with saline solution)
Study: 11818641
Drug: abciximab plus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab plus low-dose heparin
Study: 10859283
Drug: standard-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard-dose heparin
Study: 10362368
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR 2.0 to 2.5) and Aspirin (150 mg) daily
Study: 10362368
Drug: Aspirin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (150 mg) alone
Study: 2344298
Drug: Dietary cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cholesterol (700 mg/day of egg yolk cholesterol)
Study: 7149451
Drug: Inspiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Muscle Training (IMT) consisting of breathing through an inspiratory resistance (IR) for 15 min twice daily for 4 weeks
Study: 26238707
Drug: Alisporivir 600
Normalized name: Alisporivir
DrugBank: Alisporivir (DB12139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisporivir 600 mg once daily with peginterferon-α2a and ribavirin (PR)
Study: 26238707
Drug: Alisporivir 400
Normalized name: Alisporivir
DrugBank: Alisporivir (DB12139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisporivir 400 mg twice daily with peginterferon-α2a and ribavirin (PR)
Study: 24332123
Drug: DC-5ARI (discontinue
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC-5ARI (discontinue 5α-reductase inhibitor)
Study: 24332123
Drug: DC-α-blocker (discontinue
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC-α-blocker (discontinue α-blocker)
Study: 24332123
Drug: DC-α-blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DC-α-blocker
Study: 19028052
Drug: Cold crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold crystalloid (4 degrees C lactated Ringer's solution)
Study: 9626838
Drug: Endothelin-1 infusion
Normalized name: nitric oxide synthase endothelial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin-1 infusion
Study: 7933325
Drug: Trivalent split‐antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent split‐antigen vaccine containing A/Beijing/352/89 (H3N2) and B/Bangkok/163/90 (B/Panama/45/90‐like strain)
Study: 3261766
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of phenol (5%) in arachis oil with bulk laxative (Group 1)
Study: 3261766
Drug: Bulk laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulk laxative alone (Group 2)